<!DOCTYPE html>
<html lang="en">
  
<!-- Mirrored from www.allindianpatents.com/patents/206546-topically-applicable-solution by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 04:24:57 GMT -->
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=utf-8" /><!-- /Added by HTTrack -->
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=Edge,chrome=1">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Indian Patents. 206546:TOPICALLY APPLICABLE SOLUTION</title>
    <meta content="authenticity_token" name="csrf-param" />
<meta content="cYcP52B8zyTWKbLwby2YPh9z/gvY/RLjWOwY4YXkiXg=" name="csrf-token" />

    <!-- Le HTML5 shim, for IE6-8 support of HTML elements -->
    <!--[if lt IE 9]>
      <script src="//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.6.1/html5shiv.js" type="text/javascript"></script>
    <![endif]-->

    <link href="../assets/application-e80cf34975c5b1730c80b2f7170e7d26.css" media="all" rel="stylesheet" type="text/css" />

  </head>
  <body>

    <div class="navbar navbar-fluid-top">
      <div class="navbar-inner">
        <div class="container-fluid">
          <a class="btn btn-navbar" data-target=".nav-collapse" data-toggle="collapse">
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
          </a>
          <a class="brand" href="../index.html">Indian Patents</a>
          <div class="container-fluid nav-collapse">
            <ul class="nav">
              <li><a href="../recently-granted.html">Recently Granted Patents</a></li>
              <li><a href="../recently-published.html">Recently Published Patents</a></li>
            </ul>
            <form id="gform" class="navbar-search pull-right" action="https://www.google.com/search" method="get" target="_blank" onsubmit="document.getElementById('gform').q.value='site:http://www.allindianpatents.com '+document.getElementById('gform').q.value">
                <input type="text" name="q" id="q" class="search-query" placeholder="Search" onclick="this.value=''" autocomplete="off">
            </form>
          </div><!--/.nav-collapse -->
        </div>
      </div>
    </div>

    <div class="container-fluid">
      <div class="row-fluid">
        <div class="span12">

          <style>
          .allindianpatents-top { width: 320px; height: 50px; }
          @media(min-width: 500px) { .allindianpatents-top { width: 468px; height: 60px; } }
          @media(min-width: 800px) { .allindianpatents-top { width: 728px; height: 90px; } }
          </style>
          <center>
          </center>
          
          <div class="row-fluid">
	<div class="span8">

		<table class="table">
			<tr>
				<th>Title of Invention</th>
				<td><h1 style="font-size:large;">TOPICALLY APPLICABLE SOLUTION</h1></td>
			</tr>
			<tr>
				<th>Abstract</th>
				<td>Topically applicable solution for the treatment of late phase reaction associated with allergic rhinitis or conjunctivitis characterized in that it is consisting of: (a) epinastine as the only pharmaceutically active ingredient, optionally in the form of its racemate, its enantiomers, and optionally in the form of the pharmacologically acceptable acid addition salts thereof, in a concentration of 0.0005 to 1.0 wt.%, (b) water or physiological saline as solvent, (c) a buffer to adjust the pH to a value of 6.5 to 7.2, optionally by the addition of sodium hydroxide (d) a preservative, and optionally (e) chelating agents, (f) viscosity agents, (g) penetration promoters, (h) antioxidants, (i) and/or physiologically acceptable agents to adjust the tonicity of the solution.</td>
			</tr>
		</table>

					<style>
					.allindianpatents-post-abstract { width: 320px; height: 50px; }
					@media(min-width: 880px) { .allindianpatents-post-abstract { width: 468px; height: 60px; } }
					@media(min-width: 1267px) { .allindianpatents-post-abstract { width: 728px; height: 90px; } }
					</style>
					<center>
					<script async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script>
					<!-- AllIndianPatents-post-abstract -->
					<ins class="adsbygoogle allindianpatents-post-abstract"
					     style="display:inline-block"
					     data-ad-client="ca-pub-7914358224572760"
					     data-ad-slot="9152759240"></ins>
					<script>
					(adsbygoogle = window.adsbygoogle || []).push({});
					</script>					
					</center>

		<table class="table">
			<tr>
				<th>Full Text</th>
				<td>FORM 2<br>
THE PATENTS ACT 1970<br>
[39 OF 1970]<br>
&amp;<br>
THE PATENTS RULES, 2003<br>
COMPLETE SPECIFICATION<br>
[See Section 10; rule 13]<br>
"TOPICALLY APPLICABLE SOLUTION"<br>
BOEHRINGER    INGELHEIM    INTERNATIONAL    GMBH,     a    German company, of Binger Strasse 173, D-55216 Ingelheim am Rhein, Germany,<br>
The following specification particularly describes the invention and the manner in which it is to be performed:<br><br><br>
The present invention relates to topically applicable solution.<br>
The invention relates to topically administered aqueous solutions containing epinastin, optionally in the form of its racemates, its enantiomers and optionally in the form of the pharmacologically acceptable acid addition salts thereof.<br>
Background of the Invention Allergic reactions of the eye (hereinafter referred to as ocular allergic reactions) signifies a series of differently defined syndromes.  The following are' examples of ocular allergic reactions, e.g.: seasonal allergic conjunctivitis, perennial allergic conjunctivitis, giant cell conjunctivitis, vernal keratoconjunctivitis or atopic keratoconjunctivitis.  Examples of allergic reactions of the nose (hereinafter referred to as nasal allergic reactions) include seasonal allergic rhinitis and perennial allergic rhinitis, for example.<br>
The immunological mechanism on which ocular and nasal allergic reactions are based comprises inter alia inflammatory processes caused by histamine.  The allergic reactions produced by the release of histamine occur at an early stage of the ocular and nasal allergic reactions mentioned above.<br>
Moreover, ocular and nasal allergic reactions may be due to the release of other mast cell mediators as well as toxic eosinophilic granule proteins and enzymes.  The influx of neutrophils and eosinophils into the tissue of the ocular conjunctiva and the nasal mucous- membrane leads to a late phase reaction, hereinafter referred to as LPR.<br><br>
LPR normally occurs within a period of 3-6 hours after the initial histamine-mediated allergic reaction.  LPR is also characterised by the occurrence of vasodilation and chemosis and by the swelling of the conjunctiva and the nasal mucous membrane.<br>
Whereas histamine-produced allergic reactions can be counteracted by administering antihistamines, the influx of neurophils and eosinophils into the tissue of the ocular conjunctiva and the nasal mucous membrane remains unaffected by administering pure antihistamines.<br>
Problem of the Invention The problem of the present invention is therefore to provide topically administerable solutions which inhibit the influx of neutrophils and eosinophils into the tissue of the ocular conjunctiva and the nasal mucous membrane, thereby reducing or preventing the occurrence of LPR and are therefore characterised by a longer lasting duration of activity.<br>
More Detailed Description of the Invention It has been found, surprisingly, that topically administerable aqueous solutions containing epinastin, optionally in the form of its racemate, its enantiomers and possibly in the form of the pharmacologically acceptable acid addition salts thereof, may be used to solve the problem on which the invention is based, since they inhibit the influx of neutrophils and eosinophils into the tissue of the ocular conjunctiva and nasal mucous membrane, thereby reducing or preventing the occurrence of LPR and are accordingly characterised by a longer lasting duration of activity.<br>
The compound epinastin (3-amino-9,13b-dihydro-lH-dibenz-[c,f]imidazol[1,5-a]azepine) and the acid addition salts<br><br>
thereof are described for the first time in German Patent Application P 30 08 944.2.<br>
The effect of the topically administered solutions containing epinastin as inhibitors of the influx of eosinophils and neutrophils was demonstrated using the so-called passive ocular anaphylaxis model in rats.<br>
Description of Experiment:<br>
72 hours after the rats have been sensitised by injecting antiserum into the eyelids of the test animals, a fresh provocation was induced in them by intravenous administration of ovalbumin.  Some of the experimental animals were pretreated by the administration of solution containing epinastin according to the invention into the conjunctival sac 15 minutes before the ovalbumin is administered.  Two hours after the administration of ovalbumin the experimental animals were killed and the conjunctiva was investigated for its content of eosinophils and neutrophils and the mast cell granulation was determined.<br>
Results:<br>
The animals pretreated with epinastin solution according to the invention (0.05-0.5%) had a significantly lower content of eosinophils in their conjunctiva.  The animals pretreated with epinastin solution according to the invention had a significantly lower content of lymphocytes in their conjunctiva (p
Consequently, the invention relates to topically administered aqueous solutions containing epinastin, optionally in the form of its racemate, its enantiomers<br><br>
and optionally in the form of the pharmacologically acceptable addition salts thereof, in a concentration of 0.005 to 0.5, preferably 0.02 to 0.1, most preferably 0.03 to 0.07 mg/ml of solution.<br>
The above-mentioned topically administered aqueous solutions containing epinastin hydrochloride are preferred according to the invention.<br>
Suitable aqueous solvents are physiologically acceptable aqueous solvents, physiologically acceptable saline solutions being particularly preferred.<br>
According to the invention, topically administered solutions are preferably prepared which typically contain 0.005 to 0.5, preferably 0.02 to 0.1, most preferably 0.03 to 0.07 mg/ml of epinastin, optionally in the form of its racemate, its enantiomers and optionally in the form of the pharmacologically acceptable acid addition salts thereof, as well as physiological saline solutions as the main carriers.  The pH of the solutions according to the invention should preferably be maintained within the range from 6.5 - 7.2 by means of a suitable buffer system.  The preparations may also contain conventional, pharmaceutically acceptable excipients, preservatives, stabilisers and/or penetration promoters.<br>
The preferred carrier which may be used in the solutions according to the invention is purified water and preferably a physiological saline solution.<br>
Without restricting the subject matter of the invention to the following, the excipients which may be used according to the invention include viscosity agents such as polyvinyl alcohol, povidone, hydroxypropylmethylcellulose,<br><br>
poloxamers, carboxymethylcellulose, carbomers and hydroxyethylcellulose.<br>
Without restricting the subject matter of the invention to the following, the preferred preservatives which may be used in the solutions according to the invention include benzalkonium chloride, chlorobutanol, thimerosal, phenyl mercury acetate and phenyl mercury nitrate.<br>
The penetration promoters may be, for example, surfactants, specific organic solvents such as dimethylsulphoxide and other sulphoxides, dimethylacetamide and pyrrolidone, specific amides of heterocyclic amines, glycols such as propyleneglycol, propylene carbonate, oleic acid, alkylamines and derivatives thereof, various cationic, anionic, non-ionogenic and amphoteric surfactants and the like.<br>
Substances may be added as necessary or as desired in order to adjust the tonicity of the solution.  Such substances include salts and especially sodium chloride, potassium chloride, mannitol and glycerol or other suitable physiologically acceptable agents for adjusting tonicity, without restricting the invention to the above.<br>
Various buffers and substances may be used to adjust the pH, provided that the preparation obtained is physiologically acceptable.  These buffers might include acetate buffer, citrate buffer, phosphate buffer and borate buffer.<br>
Similarly, physiologically acceptable antioxidants which may be used according to the invention include sodium metabisulphite, sodium thiosulphate, acetylcysteine, butylated hydroxyanisole and butylated hydroxytoluene, without restricting the invention to this list.<br><br>
Other carrier components which may be incorporated in the solutions according to the invention are chelating agents. The preferrred chelating agent is disodium edetate (Na-EDTA) , although other chelating agents may also be used instead of or  in conjunction with disodium edetate.<br>
The above-mentioned topically administered aqueous solutions according to the invention may be applied either to the conjunctiva or to the nasal mucous membrane. Solutions for ophthalmic use are of equal importance to solutions for nasal application for the purposes of the present invention.<br>
The invention relates not only to the solutions according to the invention mentioned hereinbefore but also to the use of the above-mentioned topically administered aqueous solutions for inhibiting the influx of neutrophils and eosinophils into the tissue of the ocular conjunctiva or the tissue of the nasal mucous membrane.<br>
The present invention also relates to the use of epinastin, optionally in the form of its racemate, its enantiomers and optionally in the form of the pharmacologically acceptable acid addition salts thereof, for producing the topically administered aqueous solutions according to the invention for treating disorders of the ocular conjunctiva or the nasal mucous membranes in which there is therapeutic value in inhibiting the influx of neutrophils and eosinophils into the tissue of the ocular conjunctiva or the nasal mucous membrane in allergic reactions.<br>
The above-mentioned use for inhibiting LPR is preferred, whilst it is particularly preferable to use the preparation to treat the diseases listed at the beginning.<br><br>
The Examples shown in Table 1 illustrate the invention without restricting it.<br><br>
Table 1:	Solution 1<br>
0.05% [g/100ml]	Solution 2<br>
0.01% [g/100ml]	Solution 3<br>
0.05% [g/100mgl]	Solution 4<br>
0.10% [g/100ml]	Solution 5<br>
0.01% [g/100ml]	Solution 6<br>
0.05% [g/100ml]	Solution 7<br>
0.10% [g/100ml]<br>
Epinastin-hydrochloride	0.0500	0.0100	0.0500	0.1000	0.0100	0.0500	0.1000<br>
Na-EDTA	0.0500	0.0500	0.0500	0.0500	-	-	-<br>
Sodium chloride	0.5000	0.5000	0.5000	0.5000	0.5000	0.5000	0.5000<br>
Sodium dihydrogen phosphate dihydrate	0.7800	0.7800	0.7800	0.7800	0.4100	-0.4100	0.4100<br>
Benzalkonium chloride	0.0101	0.0101	0.0101	0.0101	0.0101	0.0101	0.0101<br>
Sodium hydroxide	0.0001	0.0001	0.0001	0.0001	-	-	-<br>
Sodium dihydrogen phosphate dihydrate	-	-	-	-	0.6500	0.6500	0.6500<br>
Hydroxyethylceliulose	-	-	-	-	0.1000	0.1000	0.1000<br>
Water	99.4198	99.4598	99.4198	99.3698	99.0749	99.0349	99.9849<br>
	100.8100	100.8100	100.8100	100.8100	100.7550	100.7550	100.7550<br><br>
We Claim:<br>
1.	Topically applicable solution for the treatment of late phase reaction<br>
associated with allergic rhinitis or conjunctivitis characterized in that it is<br>
consisting of:<br>
(a)	epinastine as the only pharmaceutically active ingredient, optionally in the form of its racemate, its enantiomers, and optionally in the form of the pharmacologically acceptable acid addition salts thereof, in a concentration of 0.0005 to 1.0 wt.%,<br>
(b)	water or physiological saline as solvent,<br>
(c)	a buffer to adjust the pH to a value of 6.5 to 7.2, optionally by the addition of sodium hydroxide<br>
(d)	a preservative, and optionally<br>
(e)	chelating agents,<br>
(f)	viscosity agents,<br>
(g)	penetration promoters,<br>
(h)      antioxidants,<br>
(i) and/or physiologically acceptable agents to adjust the tonicity of the solution.<br>
2.	Solution as claimed in claim 1, wherein epinastine is present as epinastine-hydrochloride.<br>
3.	Solution as claimed in claim 1, wherein the viscosity agent is selected from the group of polyvinyl alcohol, povidone, hydroxypropylmethylcellulose, poloxamers, carboxymethyl-cellulose, carbomers and hydroxyethylcellulose.<br>
4.	Solution as claimed in claim 1, wherein said preservative is selected from the group of benzalkonium chloride, chlorobutanol, thimerosal, phenyl mercury acetate and phenyl mercury nitrate.<br>
5.	Solution as claimed in claim 1, wherein said penetration promoter is  selected from the  group of dimethylsulphoxide,  dimethylacetamide,<br><br>
pyrrolidone, propyleneglycol, propylene carbonate and oleic acid.<br>
6.	Solution as claimed in claim 1, wherein said substances to adjust the tonicity of the solution is selected from the group of sodium chloride, potassium chloride, mannitol and glycerol.<br>
7.	Solution as claimed in claim 1 wherein said buffer is selected from the group of acetate buffer, citrate buffer, phosphate buffer and borate buffer.<br>
8.	Solution as claimed in claim 1, wherein said antioxidant is selected from the group of sodium metabisulphite, sodium thiosulphate, acetylcysteine, butylated hydroxyanisole and butylated hydroxytoluene.<br>
9.	Solution as claimed in claim 1, wherein said chelating agent is disodium edetate.<br>
10.	Solution as claimed in claim 1, wherein said solution contain water as solvent, epinastine-hydrochloride, sodium chloride, sodium-hydrogenphosphate-dihydrate, benzalkoniumchloride, hydroxylethyl-cellulose and optionally sodium-EDTA and sodium hydroxide.<br>
11.	Solution as claimed in claim 1, wherein said epinastine hydrochloride as active ingredient is in a concentration of 0.05 to 0.1<br>
wt.%.<br><br>
12.	Solution as claimed in claim 1, wherein said epinastine<br>
hydrochloride as active ingredient is in a concentration of 0.005 to<br>
0.5mg/ml.<br>
Dated	this    17th     day   of       April,	2002.<br>
[RANJNA MEHTA-DUTT]<br>
OF REMFRY &amp; SAGAR<br>
ATTORNEY FOR THE APPLICANTS</td>
			</tr>
		</table>	
		<br>
		<h3>Documents:</h3>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=SU4tUENULTIwMDItMDA0OTEtTVVNLUFCU1RSQUNUKDE3LTQtMjAwMikucGRm" target="_blank" style="word-wrap:break-word;">IN-PCT-2002-00491-MUM-ABSTRACT(17-4-2002).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=SU4tUENULTIwMDItMDA0OTEtTVVNLUFCU1RSQUNUKEFNRU5ERUQpLSgzMS03LTIwMDYpLnBkZg==" target="_blank" style="word-wrap:break-word;">IN-PCT-2002-00491-MUM-ABSTRACT(AMENDED)-(31-7-2006).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=SU4tUENULTIwMDItMDA0OTEtTVVNLUFCU1RSQUNUKEdSQU5URUQpLSgzMC00LTIwMDcpLnBkZg==" target="_blank" style="word-wrap:break-word;">IN-PCT-2002-00491-MUM-ABSTRACT(GRANTED)-(30-4-2007).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=aW4tcGN0LTIwMDItMDA0OTEtbXVtLWNhbmNlbGxlZCBwYWdlcygwNC0wMS0yMDA3KS5wZGY=" target="_blank" style="word-wrap:break-word;">in-pct-2002-00491-mum-cancelled pages(04-01-2007).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=SU4tUENULTIwMDItMDA0OTEtTVVNLUNBTkNFTExFRCBQQUdFUygzMS03LTIwMDYpLnBkZg==" target="_blank" style="word-wrap:break-word;">IN-PCT-2002-00491-MUM-CANCELLED PAGES(31-7-2006).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=SU4tUENULTIwMDItMDA0OTEtTVVNLUNMQUlNUygxNy00LTIwMDIpLnBkZg==" target="_blank" style="word-wrap:break-word;">IN-PCT-2002-00491-MUM-CLAIMS(17-4-2002).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=SU4tUENULTIwMDItMDA0OTEtTVVNLUNMQUlNUyhBTUVOREVEKS0oNC0xLTIwMDcpLnBkZg==" target="_blank" style="word-wrap:break-word;">IN-PCT-2002-00491-MUM-CLAIMS(AMENDED)-(4-1-2007).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=aW4tcGN0LTIwMDItMDA0OTEtbXVtLWNsYWltcyhncmFudGVkKS0oMDQtMDEtMjAwNykuZG9j" target="_blank" style="word-wrap:break-word;">in-pct-2002-00491-mum-claims(granted)-(04-01-2007).doc</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=aW4tcGN0LTIwMDItMDA0OTEtbXVtLWNsYWltcyhncmFudGVkKS0oMDQtMDEtMjAwNykucGRm" target="_blank" style="word-wrap:break-word;">in-pct-2002-00491-mum-claims(granted)-(04-01-2007).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=SU4tUENULTIwMDItMDA0OTEtTVVNLUNMQUlNUyhHUkFOVEVEKS0oMzAtNC0yMDA3KS5wZGY=" target="_blank" style="word-wrap:break-word;">IN-PCT-2002-00491-MUM-CLAIMS(GRANTED)-(30-4-2007).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=aW4tcGN0LTIwMDItMDA0OTEtbXVtLWNvcnJlc3BvbmRlbmNlKGlwbyktKDA3LTAxLTIwMDkpLnBkZg==" target="_blank" style="word-wrap:break-word;">in-pct-2002-00491-mum-correspondence(ipo)-(07-01-2009).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=SU4tUENULTIwMDItMDA0OTEtTVVNLUNPUlJFU1BPTkRFTkNFKElQTyktKDE2LTctMjAwNykucGRm" target="_blank" style="word-wrap:break-word;">IN-PCT-2002-00491-MUM-CORRESPONDENCE(IPO)-(16-7-2007).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=aW4tcGN0LTIwMDItMDA0OTEtbXVtLWNvcnJlc3BvbmRlbmNlMSgyOS0xMi0yMDA1KS5wZGY=" target="_blank" style="word-wrap:break-word;">in-pct-2002-00491-mum-correspondence1(29-12-2005).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=aW4tcGN0LTIwMDItMDA0OTEtbXVtLWNvcnJlc3BvbmRlbmNlMigyOS0wOC0yMDA3KS5wZGY=" target="_blank" style="word-wrap:break-word;">in-pct-2002-00491-mum-correspondence2(29-08-2007).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=SU4tUENULTIwMDItMDA0OTEtTVVNLURFU0NSSVBUSU9OKENPTVBMRVRFKS0oMTctNC0yMDAyKS5wZGY=" target="_blank" style="word-wrap:break-word;">IN-PCT-2002-00491-MUM-DESCRIPTION(COMPLETE)-(17-4-2002).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=SU4tUENULTIwMDItMDA0OTEtTVVNLURFU0NSSVBUSU9OKEdSQU5URUQpLSgzMC00LTIwMDcpLnBkZg==" target="_blank" style="word-wrap:break-word;">IN-PCT-2002-00491-MUM-DESCRIPTION(GRANTED)-(30-4-2007).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=aW4tcGN0LTIwMDItMDA0OTEtbXVtLWZvcm0gMSgxNy0wNC0yMDAyKS5wZGY=" target="_blank" style="word-wrap:break-word;">in-pct-2002-00491-mum-form 1(17-04-2002).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=SU4tUENULTIwMDItMDA0OTEtTVVNLUZPUk0gMSgxNy00LTIwMDIpLnBkZg==" target="_blank" style="word-wrap:break-word;">IN-PCT-2002-00491-MUM-FORM 1(17-4-2002).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=aW4tcGN0LTIwMDItMDA0OTEtbXVtLWZvcm0gMTMoMzEtMDgtMjAwNykucGRm" target="_blank" style="word-wrap:break-word;">in-pct-2002-00491-mum-form 13(31-08-2007).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=SU4tUENULTIwMDItMDA0OTEtTVVNLUZPUk0gMTMoMzEtOC0yMDA3KS5wZGY=" target="_blank" style="word-wrap:break-word;">IN-PCT-2002-00491-MUM-FORM 13(31-8-2007).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=SU4tUENULTIwMDItMDA0OTEtTVVNLUZPUk0gMTgoMjYtMTEtMjAwNSkucGRm" target="_blank" style="word-wrap:break-word;">IN-PCT-2002-00491-MUM-FORM 18(26-11-2005).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=aW4tcGN0LTIwMDItMDA0OTEtbXVtLWZvcm0gMWEoMzEtMDctMjAwNikucGRm" target="_blank" style="word-wrap:break-word;">in-pct-2002-00491-mum-form 1a(31-07-2006).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=aW4tcGN0LTIwMDItMDA0OTEtbXVtLWZvcm0gMWEoMzEtMDgtMjAwNykucGRm" target="_blank" style="word-wrap:break-word;">in-pct-2002-00491-mum-form 1a(31-08-2007).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=aW4tcGN0LTIwMDItMDA0OTEtbXVtLWZvcm0gMihncmFudGVkKS0oMDQtMDEtMjAwNykuZG9j" target="_blank" style="word-wrap:break-word;">in-pct-2002-00491-mum-form 2(granted)-(04-01-2007).doc</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=aW4tcGN0LTIwMDItMDA0OTEtbXVtLWZvcm0gMihncmFudGVkKS0oMDQtMDEtMjAwNykucGRm" target="_blank" style="word-wrap:break-word;">in-pct-2002-00491-mum-form 2(granted)-(04-01-2007).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=SU4tUENULTIwMDItMDA0OTEtTVVNLUZPUk0gMihHUkFOVEVEKS0oMzAtNC0yMDA3KS5wZGY=" target="_blank" style="word-wrap:break-word;">IN-PCT-2002-00491-MUM-FORM 2(GRANTED)-(30-4-2007).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=SU4tUENULTIwMDItMDA0OTEtTVVNLUZPUk0gMihUSVRMRSBQQUdFKS0oR1JBTlRFRCktKDMwLTQtMjAwNykucGRm" target="_blank" style="word-wrap:break-word;">IN-PCT-2002-00491-MUM-FORM 2(TITLE PAGE)-(GRANTED)-(30-4-2007).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=aW4tcGN0LTIwMDItMDA0OTEtbXVtLWZvcm0gMygxNy0wNC0yMDAyKS5wZGY=" target="_blank" style="word-wrap:break-word;">in-pct-2002-00491-mum-form 3(17-04-2002).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=aW4tcGN0LTIwMDItMDA0OTEtbXVtLWZvcm0gMygzMS0wNy0yMDA2KS5wZGY=" target="_blank" style="word-wrap:break-word;">in-pct-2002-00491-mum-form 3(31-07-2006).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=aW4tcGN0LTIwMDItMDA0OTEtbXVtLWZvcm0gNSgxNy0wNC0yMDAyKS5wZGY=" target="_blank" style="word-wrap:break-word;">in-pct-2002-00491-mum-form 5(17-04-2002).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=aW4tcGN0LTIwMDItMDA0OTEtbXVtLWZvcm0tcGN0LWlwZWEtNDA5KDE3LTA0LTIwMDIpLnBkZg==" target="_blank" style="word-wrap:break-word;">in-pct-2002-00491-mum-form-pct-ipea-409(17-04-2002).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=aW4tcGN0LTIwMDItMDA0OTEtbXVtLWZvcm0tcGN0LWlzYS0yMTAoMTctMDQtMjAwMikucGRm" target="_blank" style="word-wrap:break-word;">in-pct-2002-00491-mum-form-pct-isa-210(17-04-2002).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=aW4tcGN0LTIwMDItMDA0OTEtbXVtLXBldGl0aW9uIHVuZGVyIHJ1bGUgMTM3KDMxLTA3LTIwMDYpLnBkZg==" target="_blank" style="word-wrap:break-word;">in-pct-2002-00491-mum-petition under rule 137(31-07-2006).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=aW4tcGN0LTIwMDItMDA0OTEtbXVtLXBldGl0aW9uIHVuZGVyIHJ1bGUgMTM4KDMxLTA3LTIwMDYpLnBkZg==" target="_blank" style="word-wrap:break-word;">in-pct-2002-00491-mum-petition under rule 138(31-07-2006).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=SU4tUENULTIwMDItMDA0OTEtTVVNLVBPV0VSIE9GIEFVVEhPUklUWSgxMy02LTIwMDIpLnBkZg==" target="_blank" style="word-wrap:break-word;">IN-PCT-2002-00491-MUM-POWER OF AUTHORITY(13-6-2002).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=aW4tcGN0LTIwMDItMDA0OTEtbXVtLXBvd2VyIG9mIGF1dGhvcml0eSgxNy0wNC0yMDAyKS5wZGY=" target="_blank" style="word-wrap:break-word;">in-pct-2002-00491-mum-power of authority(17-04-2002).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=aW4tcGN0LTIwMDItMDA0OTEtbXVtLXBvd2VyIG9mIGF1dGhvcml0eSgzMS0wNy0yMDA2KS5wZGY=" target="_blank" style="word-wrap:break-word;">in-pct-2002-00491-mum-power of authority(31-07-2006).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=SU4tUENULTIwMDItMDA0OTEtTVVNLVNQRUNJRklDQVRJT04oQU1FTkRFRCktKDMxLTctMjAwNikucGRm" target="_blank" style="word-wrap:break-word;">IN-PCT-2002-00491-MUM-SPECIFICATION(AMENDED)-(31-7-2006).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=SU4tUENULTIwMDItMDA0OTEtTVVNLVdPIElOVEVSTkFUSU9OQUwgUFVCTElDQVRJT04gUkVQT1JUKDE3LTQtMjAwMikucGRm" target="_blank" style="word-wrap:break-word;">IN-PCT-2002-00491-MUM-WO INTERNATIONAL PUBLICATION REPORT(17-4-2002).pdf</a></p>
		<br>
		<div class="pull-left">
			<a href="206545-imidazo-1-2-a-pyridine-and-pyrazolo-2-3-a-pyridine-derivatives.html">&laquo; Previous Patent</a>
		</div>
		<div class="pull-right">
			<a href="206547-a-garbage-storage-and-compression-method-for-economical-disposal.html">Next Patent &raquo;</a>
		</div>			
	</div><!-- /span8 -->
	<div class="span4">
		<div class="well infobox">
			<table class="table table-condensed">
				<tr>
					<th>Patent Number</th>
					<td>206546</td>
				</tr>
				<tr>
					<th>Indian Patent Application Number</th>
					<td>IN/PCT/2002/00491/MUM</td>
				</tr>
				<tr>
					<th>PG Journal Number</th>
					<td>30/2007</td>
				</tr>
				<tr>
					<th>Publication Date</th>
					<td>27-Jul-2007</td>
				</tr>
				<tr>
					<th>Grant Date</th>
					<td>30-Apr-2007</td>
				</tr>
				<tr>
					<th>Date of Filing</th>
					<td>17-Apr-2002</td>
				</tr>
				<tr>
					<th>Name of Patentee</th>
					<td>BOEHRINGER INGELHEIM INTERNATIONAL GMBH</td>
				</tr>
				<tr>
					<th>Applicant Address</th>
					<td>BINGER STRASSE 173, D-55216 INGELHEIM AM RHEIN, GERMANY.</td>
				</tr>
				<tr>
					<td colspan=2>
								<h5>Inventors:</h5>
								<table class="table">
									<tr>
										<th>#</th>
										<th>Inventor's Name</th>
										<th>Inventor's Address</th>
									</tr>

										<tr>
											<td>1</td>
											<td>VOLKER TRACH</td>
											<td>PROBSTSTR. 7, D-88400 BIBERACH, GERMANY.</td>
										</tr>
										<tr>
											<td>2</td>
											<td>GEROLD DUSCHLER</td>
											<td>AM STADION 9, D-89584 EHINGEN, GERMANY.</td>
										</tr>
								</table>
					</td>
				</tr>
				<tr>
					<th>PCT International Classification Number</th>
					<td>A61K 31/55</td>
				</tr>
				<tr>
					<th>PCT International Application Number</th>
					<td>PCT/EP00/10122</td>
				</tr>
				<tr>
					<th>PCT International Filing date</th>
					<td>2000-10-14</td>
				</tr>
				<tr>
					<td colspan=2>
						<h5>PCT Conventions:</h5>
						<table class="table">
							<tr>
								<th>#</th>
								<th>PCT Application Number</th>
								<th>Date of Convention</th>
								<th>Priority Country</th>
							</tr>

								<tr>
									<td>1</td>
									<td>199 54 516.2</td>
									<td>1999-11-12</td>
								    <td>Germany</td>
								</tr>

						</table>
					</td>
				</tr>
			</table>
		</div><!-- /well -->
	</div><!-- /span4 -->
</div><!-- /row-fluid -->

        </div>

      </div><!--/row-->

      <footer class="footer">

        <style>
        .allindianpatents-footer { width: 320px; height: 50px; }
        @media(min-width: 500px) { .allindianpatents-footer { width: 468px; height: 60px; } }
        @media(min-width: 800px) { .allindianpatents-footer { width: 728px; height: 90px; } }
        </style>
        <center>
        </center>

        <p>&copy; All Indian Patents, 2013-2021.</p>
        <p>Patent data available in the public domain from Indian Patents Office, Department of Industrial Policy and Promotions, Ministry of Commerce and Industry, Government of India.</p>
      </footer>

    </div> <!-- /container -->

    <!-- Javascripts
    ================================================== -->
    <!-- Placed at the end of the document so the pages load faster -->
    <script src="../assets/application-95f297ff0d8d2015987f04b30593c800.js" type="text/javascript"></script>

    <!-- Start of StatCounter Code for Default Guide -->
    <script type="text/javascript">
    var sc_project=8902313; 
    var sc_invisible=1; 
    var sc_security="3c1f8147"; 
    var scJsHost = (("https:" == document.location.protocol) ?
    "https://secure." : "http://www.");
    document.write("<sc"+"ript type='text/javascript' src='" +
    scJsHost+
    "statcounter.com/counter/counter.js'></"+"script>");
    </script>
    <noscript><div class="statcounter"><a title="web stats"
    href="http://statcounter.com/free-web-stats/"
    target="_blank"><img class="statcounter"
    src="http://c.statcounter.com/8902313/0/3c1f8147/1/"
    alt="web stats"></a></div></noscript>
    <!-- End of StatCounter Code for Default Guide -->

    <script>
      (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
      (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
      m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
      })(window,document,'script','http://www.google-analytics.com/analytics.js','ga');

      ga('create', 'UA-244143-31', 'allindianpatents.com');
      ga('send', 'pageview');

    </script>

  </body>

<!-- Mirrored from www.allindianpatents.com/patents/206546-topically-applicable-solution by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 04:24:58 GMT -->
</html>
